What is Erste Group Bank’s Estimate for NVO FY2026 Earnings?

Novo Nordisk A/S (NYSE:NVO) – Analysts at Erste Group Bank cut their FY2026 earnings estimates for Novo Nordisk A/S in a research report issued on Thursday, June 25th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.23 per share for the year, down from their prior estimate of $3.27. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.41 per share.

NVO has been the topic of a number of other reports. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective on the stock. Finally, TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research report on Tuesday, March 10th. Five investment analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $48.69 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The company’s fifty day moving average price is $44.25 and its two-hundred day moving average price is $45.81. The firm has a market capitalization of $217.40 billion, a P/E ratio of 11.43, a P/E/G ratio of 4.33 and a beta of 0.77. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in NVO. Confluence Investment Management LLC grew its position in Novo Nordisk A/S by 10.8% during the 2nd quarter. Confluence Investment Management LLC now owns 17,385 shares of the company’s stock worth $833,000 after purchasing an additional 1,699 shares in the last quarter. Western Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S by 89.9% during the first quarter. Western Wealth Management LLC now owns 16,271 shares of the company’s stock valued at $598,000 after buying an additional 7,703 shares in the last quarter. Shariaportfolio Inc. acquired a new stake in Novo Nordisk A/S during the 1st quarter worth about $1,146,000. LFG Wealth Partners LLC purchased a new position in Novo Nordisk A/S during the 1st quarter valued at about $1,071,000. Finally, Rathbones Group PLC increased its holdings in shares of Novo Nordisk A/S by 12.0% in the 1st quarter. Rathbones Group PLC now owns 81,882 shares of the company’s stock valued at $3,009,000 after purchasing an additional 8,744 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Medicare is starting temporary coverage for GLP-1 obesity treatments, including Novo Nordisk’s Wegovy injection and tablet, which could broaden access and increase demand for the company’s weight-loss drugs. Medicare will start covering obesity drugs for the first time. Here’s what patients should know
• Positive Sentiment: Shantha Biologics announced an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India, a move that could help strengthen supply and support future product demand. Shantha Biologics Announces Cartridge Fill-Finish Collaboration
• Positive Sentiment: Nordea upgraded Novo Nordisk to Buy, signaling improved analyst confidence in the stock’s valuation and dividend appeal. Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why
• Positive Sentiment: Shares also rose after the company was highlighted as outperforming the broader market in recent trading, reflecting investor appetite for the name amid obesity-drug optimism. Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: News coverage around weight-loss ETFs and broader obesity-treatment investing reinforces sector interest, but it is more of a thematic tailwind than a direct catalyst for Novo Nordisk. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS estimate slightly, which is a modest cautionary note, though it did not change the broader longer-term growth story. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.